Prevalence and Determinants of Endothelial Dysfunction Among Adults Living with HIV in Northwest Nigeria

Overview

Journal Glob Heart

Publisher Ubiquity Press

Specialty Cardiology & Vascular Diseases

Date 2023 Oct 23

PMID 37868129

Authors

Aisha M Nalado

Bala Waziri

Anas Ismail

Nafiu Umar

Zainab U Ibrahim

Patience Obiagwu

Baba M Musa

Mahmoud U Sani

Aliyu Abdu

Faisal S Dankishiya

Mansur A Ramalan

Hadiza Saidu

Usman J Wudil

C William Wester

Muktar H Aliyu

Affiliations

Soon will be listed here.

Abstract

Background: Endothelial dysfunction constitutes an early pathophysiological event in atherogenesis and cardiovascular disease. This study aimed to assess the prevalence, determinants, and degree of endothelial dysfunction in antiretroviral therapy (ART)-treated people living with HIV (PLWH) in northwestern Nigeria using brachial flow-mediated dilatation (FMD).

Methods: This was a comparative, cross-sectional study. A total of 200 ART-treated adults living with HIV with no evidence of kidney disease were compared with 200 HIV-negative participants attending a tertiary hospital in Kano, Nigeria, between September 2020 and May 2021. Endothelial function was evaluated by measuring FMD with a high-resolution vascular ultrasound transducer. FMD was calculated as the ratio of the brachial artery diameter after reactive hyperemia to baseline diameter and expressed as a percentage of change. Blood and urine samples were obtained from participants in both arms. Urine albumin-to-creatinine ratio (uACR) was calculated using the 2021 CKD-EPI estimated glomerular filtration rate (eGFR) creatinine-cystatin C equation without the race variable, and low-density lipoprotein (LDL) cholesterol was measured using enzymatic method.

Results: The overall mean age (± standard deviation) of the study participants was 42 ± 11 years. Participants in the comparison arm were younger than PLWH (38 ± 11 versus 46 ± 10 years, respectively). The median (interquartile range) uACR was 41.6 (23.2-162.9) mg/g for the ART-treated PLWH versus 14.5 (7.4-27.0) mg/g for healthy controls. PLWH had a significantly lower mean percent FMD when compared to HIV-negative participants (9.8% ± 5.4 versus 12.1% ± 9.2, respectively). Reduced FMD was independently associated with HIV infection (β = -2.83%, 95% CI, -4.44% to -1.21%, = 0.001), estimated glomerular filtration rate (β = -0.04%, 95% CI, -0.07% to -0.01%, = 0.004) and LDL cholesterol (β = -1.12%, 95% CI, -2.13% to -0.11%, = 0.029).

Conclusion: HIV-positive status, lower estimated GFR, and higher LDL cholesterol levels were independently associated with endothelial dysfunction. Future prospective studies with larger cohorts of persons living with HIV (and age- and sex-matched HIV-negative controls) are needed to gain further insight into these important findings. In the interim, aggressive management of modifiable risk factors is warranted.

References

Bonnet D, Aggoun Y, Szezepanski I, Bellal N, Blanche S . Arterial stiffness and endothelial dysfunction in HIV-infected children. AIDS. 2004; 18(7):1037-41. DOI: 10.1097/00002030-200404300-00012. View

Nkeh-Chungag B, Goswami N, Engwa G, Sewani-Rusike C, Mbombela V, Webster I . Relationship between Endothelial Function, Antiretroviral Treatment and Cardiovascular Risk Factors in HIV Patients of African Descent in South Africa: A Cross-Sectional Study. J Clin Med. 2021; 10(3). PMC: 7864186. DOI: 10.3390/jcm10030392. View

Solages A, Vita J, Thornton D, Murray J, Heeren T, Craven D . Endothelial function in HIV-infected persons. Clin Infect Dis. 2006; 42(9):1325-32. PMC: 2737346. DOI: 10.1086/503261. View

Torriani F, Komarow L, Parker R, Cotter B, Currier J, Dube M . Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol. 2008; 52(7):569-76. PMC: 2603599. DOI: 10.1016/j.jacc.2008.04.049. View

Singh A, Satchell S . Microalbuminuria: causes and implications. Pediatr Nephrol. 2011; 26(11):1957-65. PMC: 3178015. DOI: 10.1007/s00467-011-1777-1. View

Arnaiz de Las Revillas F, Gonzalez-Quintanilla V, Parra J, Palacios E, Gonzalez-Rico C, Arminanzas C . Evaluation of endothelial function and subclinical atherosclerosis in patients with HIV infection. Sci Rep. 2021; 11(1):18431. PMC: 8446055. DOI: 10.1038/s41598-021-97795-2. View

Lorenz M, Stephan C, Harmjanz A, Staszewski S, Buehler A, Bickel M . Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis. 2007; 196(2):720-6. DOI: 10.1016/j.atherosclerosis.2006.12.022. View

Fourie C, Schutte A, Smith W, Kruger A, van Rooyen J . Endothelial activation and cardiometabolic profiles of treated and never-treated HIV infected Africans. Atherosclerosis. 2015; 240(1):154-60. DOI: 10.1016/j.atherosclerosis.2015.03.015. View

Stein J, Kime N, Korcarz C, Ribaudo H, Currier J, Delaney J . Effects of HIV Infection on Arterial Endothelial Function: Results From a Large Pooled Cohort Analysis. Arterioscler Thromb Vasc Biol. 2020; 41(1):512-522. PMC: 7770018. DOI: 10.1161/ATVBAHA.120.315435. View

10.

Strijdom H, De Boever P, Walzl G, Essop M, Nawrot T, Webster I . Cardiovascular risk and endothelial function in people living with HIV/AIDS: design of the multi-site, longitudinal EndoAfrica study in the Western Cape Province of South Africa. BMC Infect Dis. 2017; 17(1):41. PMC: 5219697. DOI: 10.1186/s12879-016-2158-y. View

11.

Bush K, Teel J, Watts J, Gore R, Alvarado G, Harper N . Association of Endothelial Dysfunction and Antiretroviral Therapy in Early HIV Infection. JAMA Netw Open. 2019; 2(10):e1913615. PMC: 6813669. DOI: 10.1001/jamanetworkopen.2019.13615. View

12.

Stein J, Klein M, Bellehumeur J, McBride P, Wiebe D, Otvos J . Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation. 2001; 104(3):257-62. DOI: 10.1161/01.cir.104.3.257. View

13.

Corretti M, Anderson T, Benjamin E, Celermajer D, Charbonneau F, Creager M . Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002; 39(2):257-65. DOI: 10.1016/s0735-1097(01)01746-6. View

14.

Thijssen D, Black M, Pyke K, Padilla J, Atkinson G, Harris R . Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. Am J Physiol Heart Circ Physiol. 2010; 300(1):H2-12. PMC: 3023245. DOI: 10.1152/ajpheart.00471.2010. View

15.

Juonala M, Viikari J, Laitinen T, Marniemi J, Helenius H, Ronnemaa T . Interrelations between brachial endothelial function and carotid intima-media thickness in young adults: the cardiovascular risk in young Finns study. Circulation. 2004; 110(18):2918-23. DOI: 10.1161/01.CIR.0000147540.88559.00. View

16.

Bonou M, Kapelios C, Athanasiadi E, Mavrogeni S, Psichogiou M, Barbetseas J . Imaging modalities for cardiovascular phenotyping in asymptomatic people living with HIV. Vasc Med. 2021; 26(3):326-337. DOI: 10.1177/1358863X20978702. View

17.

Vachiat A, Dix-Peek T, Duarte R, Manga P . Endothelial dysfunction in HIV-positive patients with acute coronary syndromes. Cardiovasc J Afr. 2020; 31(4):58-64. DOI: 10.5830/CVJA-2019-040. View

18.

Mu H, Chai H, Lin P, Yao Q, Chen C . Current update on HIV-associated vascular disease and endothelial dysfunction. World J Surg. 2007; 31(4):632-43. DOI: 10.1007/s00268-006-0730-0. View

19.

Huhn G, Shamblaw D, Baril J, Hsue P, Mills B, Nguyen-Cleary T . Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate. Open Forum Infect Dis. 2020; 7(1):ofz472. PMC: 6954396. DOI: 10.1093/ofid/ofz472. View

20.

Widlansky M, Gokce N, Keaney Jr J, Vita J . The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003; 42(7):1149-60. DOI: 10.1016/s0735-1097(03)00994-x. View